Immunotherapy for HCC: limitations in patients with NASH

被引:4
作者
Agarwal, Parul D. [1 ]
Lucey, Michael R. [1 ]
Said, Adnan [1 ]
Kratz, Jeremy [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, 4224 MFCB,1685 Highland Ave, Madison, WI 53705 USA
关键词
HEPATOCELLULAR-CARCINOMA; SORAFENIB; MANAGEMENT;
D O I
10.1016/j.aohep.2022.100886
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页数:3
相关论文
共 23 条
[1]   Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].
Abou-Alfa, G. K. ;
Meyer, T. ;
Cheng, A. -L. ;
El-Khoueiry, A. B. ;
Rimassa, L. ;
Ryoo, B. -Y. ;
Cicin, I. ;
Merle, P. ;
Chen, Y. H. ;
Park, J. -W. ;
Blanc, J. -F. ;
Bolondi, L. ;
Klumpen, H. -J. ;
Chan, S. L. ;
Zagonel, V. ;
Pressiani, T. ;
Ryu, M. -H. ;
Venook, A. P. ;
Hessel, C. ;
Borgman-Hagey, A. E. ;
Schwab, G. ;
Kelley, R. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63
[2]   Multidisciplinary Management of Hepatocellular Carcinoma Improves Access to Therapy and Patient Survival [J].
Agarwal, Parul D. ;
Phillips, Paulina ;
Hillman, Luke ;
Lucey, Michael R. ;
Lee, Fred ;
Mezrich, Josh D. ;
Said, Adnan .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2017, 51 (09) :845-849
[3]   Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma [J].
Behary, Jason ;
Amorim, Nadia ;
Jiang, Xiao-Tao ;
Raposo, Anita ;
Gong, Lan ;
McGovern, Emily ;
Ibrahim, Ragy ;
Chu, Francis ;
Stephens, Carlie ;
Jebeili, Hazem ;
Fragomeli, Vincenzo ;
Koay, Yen Chin ;
Jackson, Miriam ;
O'Sullivan, John ;
Weltman, Martin ;
McCaughan, Geoffrey ;
El-Omar, Emad ;
Zekry, Amany .
NATURE COMMUNICATIONS, 2021, 12 (01)
[4]   Toxicity of sorafenib: clinical and molecular aspects [J].
Blanchet, Benoit ;
Billemont, Bertrand ;
Barete, Stephane ;
Garrigue, Helene ;
Cabanes, Laure ;
Coriat, Romain ;
Frances, Camille ;
Knebelmann, Bertrand ;
Goldwasser, Francois .
EXPERT OPINION ON DRUG SAFETY, 2010, 9 (02) :275-287
[5]   Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies [J].
Bruix, Jordi ;
Cheng, Ann-Lii ;
Meinhardt, Gerold ;
Nakajima, Keiko ;
De Sanctis, Yoriko ;
Llovet, Josep .
JOURNAL OF HEPATOLOGY, 2017, 67 (05) :999-1008
[6]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[7]  
Cheng AL, 2022, J HEPATOL, V76, P862, DOI [10.1016/j.jhep.2021.11.030, 10.1016/j.jceh.2022.07.003]
[8]   Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma [J].
Chung, Andrew S. ;
Mettlen, Marcel ;
Ganguly, Debolina ;
Lu, Tianshi ;
Wang, Tao ;
Brekken, Rolf A. ;
Hsiehchen, David ;
Zhu, Hao .
CANCER PREVENTION RESEARCH, 2020, 13 (11) :911-922
[9]   Does immune checkpoint inhibitor exhibit limited efficacy against non-viral hepatocellular carcinoma?: A review of clinical trials [J].
Eso, Yuji ;
Taura, Kojiro ;
Seno, Hiroshi .
HEPATOLOGY RESEARCH, 2022, 52 (01) :67-74
[10]   Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Qin, Shukui ;
Ikeda, Masafumi ;
Galle, Peter R. ;
Ducreux, Michel ;
Kim, Tae-You ;
Kudo, Masatoshi ;
Breder, Valeriy ;
Merle, Philippe ;
Kaseb, Ahmed O. ;
Li, Daneng ;
Verret, Wendy ;
Xu, Derek-Zhen ;
Hernandez, Sairy ;
Liu, Juan ;
Huang, Chen ;
Mulla, Sohail ;
Wang, Yulei ;
Lim, Ho Yeong ;
Zhu, Andrew X. ;
Cheng, Ann-Lii .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905